Revance Therapeutics, Inc. (RVNC) [Rocket]

Date Filed	Type	Description
04/21/2020	GN	Outlook Therapeutics Bolsters Clinical and Commercial Expertise with Two Key Appointments to Board of Directors
02/11/2019	GN	CohBar Announces the Appointment of Dr. Phyllis Gardner to its Board of Directors
11/27/2018	GN	Market Trends Toward New Normal in Palatin Technologies, Revance Therapeutics, Geo Group, QUANTENNA COMMS, The Navigators Group, and INVESCO MORTGAGE CAPITAL INC — Emerging Consolidated Expectations, Analyst Ratings
05/08/2018	BW	Revance Releases First Quarter 2018 Results
05/02/2018	GN	Factors of Influence in 2018, Key Indicators and Opportunity within Independent Bank Group, Eclipse Resources, Stellus Capital Investment, International Bancshares, Portola Pharmaceuticals, and Revance Therapeutics — New Research Emphasizes Economic Growth
04/24/2018	BW	Revance Therapeutics to Release First Quarter 2018 Financial Results on Tuesday, May 8, 2018
02/28/2018	BW	Revance Releases Fourth Quarter and Full Year 2017 Results
02/22/2018	BW	Revance Therapeutics to Release Fourth Quarter and Full Year 2017 Financial Results on Wednesday, February 28, 2018
01/03/2018	GN	Report: Exploring Fundamental Drivers Behind Blackhawk Network, TrueCar, Home BancShares, Revance Therapeutics, Heritage Financial, and GMS — New Horizons, Emerging Trends, and Upcoming Developments
12/05/2017	BW	Revance's RT002 Meets Primary and All Secondary Endpoints, Achieves 6-Month Duration in Pivotal SAKURA Phase 3 Trials for Glabellar Lines
11/02/2017	BW	Revance Releases Third Quarter 2017 Results
10/18/2017	BW	Revance Therapeutics to Release Third Quarter 2017 Financial Results Thursday, November 2, 2017
08/30/2017	BW	Revance to Participate in the 2017 Wells Fargo Securities Healthcare Conference
08/03/2017	BW	Revance Releases Second Quarter 2017 Results
07/24/2017	BW	Revance Therapeutics to Release Second Quarter 2017 Financial Results Thursday, August 3, 2017
06/01/2017	BW	Revance to Participate in Upcoming Investor Conferences